A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer

Molecular Therapy

Volumn 12, Issue 5, 2005, Pages 835-841

  Dwyer, Roisin M ^a   Schatz, Stephen M ^a   Bergert, Elizabeth R ^a   Myers, Rae M ^a   Harvey, Mary E ^a   Classic, Kelly L ^a   Blanco, Michael C ^a   Frisk, Craig S ^a   Marler, Ronald J ^b   Davis, Brian J ^a   O'Connor, Michael K ^a   Russell, Stephen J ^a   Morris, John C ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c NONE   (United States)

Author keywords

Adenovirus; Gene therapy; Prostate cancer; Radioiodine; Sodium iodide symporter

Indexed keywords

ADENOVIRUS VECTOR; IODINE 131; LIOTHYRONINE; SODIUM CHLORIDE; SODIUM IODIDE SYMPORTER; THYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE MODEL; DOG; DOSIMETRY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; GENE; HUMAN ADENOVIRUS 5; MALE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RECURRENT CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLC5A5 GENE; THYROID HORMONE SYNTHESIS; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS; HUMAN ADENOVIRUS TYPE 5;

EID: 27744563596     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.05.013     Document Type: Article

References (32)

1. A. Jemal et al. Cancer statistics, 2005 CA Cancer J. Clin. 55 2005 10-30
2. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials Lancet 355 2000 1491-1498
3. R. Foley M. Lawler and D. Hollywood Gene-based therapy in prostate cancer Lancet Oncol. 5 2004 469-479
4. 2PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer Cancer Res. 15 2003 7840-7844
5. C. Spitzweg et al. In vivo sodium iodide symporter gene therapy of prostate cancer Gene Ther. 8 2001 1524-1531
6. C. Spitzweg et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells Endocrinology 144 2003 3423-3432
7. C. Spitzweg et al. Prostate-specific antigen promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines Cancer Res. 59 1999 2136-2141
8. C. Spitzweg et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter Cancer Res. 60 2000 6526-6530
9. N. Carrasco Iodide transport in the thyroid gland Biochim. Biophys. Acta 1154 1993 65-82
10. E. Mazzaferri and R. Kloos Current approaches to primary therapy for papillary and follicular thyroid cancer J. Clin. Endocrinol. Metab. 86 2001 1447-1463
11. P. Smanik et al. Cloning of the human sodium iodide symporter Biochem. Biophys. Res. Commun. 226 1996 339-345
12. G. Dai O. Levy and N. Carrasco Cloning and characterization of the thyroid iodide transporter Nature 379 1996 458-460
13. C. Spitzweg K. Harrington L. Pinke R. Vile and J. Morris The sodium iodide symporter and its potential in cancer therapy J. Clin. Endocrinol. Metab. 86 2001 3327-3335
14. - symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid Clin. Cancer Res. 10 2004 4294-4302
15. J.-K. Chung Sodium iodide symporter: Its role in nuclear medicine J. Nucl. Med. 43 2002 1188-1200
16. - symporter (NIS): Imaging and therapeutic applications Semin. Nucl. Med. XXXIV 2004 23-31
17. J. Faivre et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in Wistar rats Cancer Res. 64 2004 8045-8051
18. I. Scholz et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer Gene Ther. 12 2004 272-280
19. T. Kogai et al. Systemic retinoic acid treatment induces sodium/iodide symporter expression and radioiodide uptake in mouse breast cancer models Cancer Res. 64 2004 415-422
20. - symporter (NIS) in a large sampling of thyroid cancer cases J. Clin. Endocrinol. Metab. 86 2001 2697-2700
21. K.M. La Perle et al. In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer Prostate 50 2002 170-178
22. E. Mitrofanova et al. Rat sodium iodide symporter for radioiodine therapy of cancer Clin. Cancer Res. 10 2004 6969-6976
23. R. Dwyer E. Bergert M. O'Connor S. Gendler and J. Morris In vivo radioiodide imaging and treatment of breast cancer xenografts following MUC1-driven expression of the sodium iodide symporter (NIS) Clin. Cancer Res. 11 2005 1483-1489
24. D. Dingli et al. Genetically targeted radiotherapy for multiple myeloma Gene Ther. 102 2003 489-496
25. K.N. Barton et al. GENIS: Gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo Mol. Ther. 8 2003 508-518
26. M. Steiner Y. Zhang J. Carraher and Y. Lu In vivo expression of prostate-specific adenoviral vectors in a canine model Cancer Gene Ther. 6 1999 456-464
27. K.N. Barton et al. A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors Mol. Ther. 9 2004 625-631
28. 132I as sodium iodide J. Nucl. Med. 16 1975 857-860
29. B. Emami et al. Tolerance of normal tissue to therapeutic irradiation Int. J. Radiat. Oncol. Biol. Phys. 21 1991 109-122
30. I.R. Hart Tissue specific promoters in targeting systemically delivered gene therapy Semin. Oncol. 23 1996 154-158
31. V. Krasnykh J.T. Douglas and V.W. Van Beusechem Genetic targeting of adenoviral vectors Mol. Ther. 1 2000 391-405
32. S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res. 62 2002 4968-4976